Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor γ overexpression in human pancreatic carcinoma

Zhang,Yan; Luo,Hui-Yan; Liu,Guang-Lin; Wang,De-Shen; Wang,Zhi-Qiang; Zeng,Zhao-Lei; Xu,Rui-Hua

doi:10.3892/ijo.2014.2709

Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor γ overexpression in human pancreatic carcinoma

Authors:
- Yan Zhang
- Hui-Yan Luo
- Guang-Lin Liu
- De-Shen Wang
- Zhi-Qiang Wang
- Zhao-Lei Zeng
- Rui-Hua Xu
View Affiliations

Affiliations: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China, Department of Radiation Oncology, The First Affiliated Hospital of Guangzhou Medical College, Guangzhou 510120, P.R. China
Published online on: October 17, 2014 https://doi.org/10.3892/ijo.2014.2709
Pages: 175-184

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated nuclear receptor which has been implicated in carcinogenesis and angiogenesis in a wide range of cancers, including pancreatic carcinoma (PC). We aimed to characterize the prognosis and potential therapeutic implications of PPARγ in PC. Real-time RT-PCR and western blotting were used to quantify PPARγ expression in immortalized pancreatic epithelial cells, PC cell lines and freshly isolated matched tumor and non-tumor tissues. PPARγ protein expression was analyzed by immunohistochemistry (IHC) in archived tumor tissues from 101 PC patients. Furthermore, the effect of PPARγ on the cytotoxic action of gemcitabine (Gem) and 5-fluorouracil (5-FU) in PC cell lines was investigated in vitro using RNA interference techniques. Both PPARγ protein and mRNA were expressed at markedly higher levels in all of the PC cell lines and freshly isolated PC tissues, compared to normal immortalized pancreatic epithelial cells and the matched adjacent non-tumor tissues. High levels of PPARγ expression correlated significantly with tumor-node-metastasis (TNM) staging (P<0.001) and poor overall survival (P<0.001), especially in patients with advanced disease who received postoperative chemotherapy. While silencing of PPARγ significantly inhibit the cytotoxic effects of both gemcitabine and 5-fluorouracil in PC cells in vitro. This study suggests that high levels of PPARγ expression are associated with poor overall survival in PC. Additionally, PPARγ promotes chemoresistance in PC cells, indicating that PPARγ may represent a novel therapeutic target for PC.

View Figures

View References

1	Pliarchopoulou K and Pectasides D: Pancreatic cancer: current and future treatment strategies. Cancer Treat Rev. 35:431–436. 2009. View Article : Google Scholar : PubMed/NCBI
2	Ramon Torrell JM and Serra Majem L: Descriptive epidemiology of cancer of the stomach in Catalonia 1983–1986. Gac Sanit. 4:76–77. 1990.(In Spanish).
3	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
4	Bardeesy N and DePinho RA: Pancreatic cancer biology and genetics. Nat Rev Cancer. 2:897–909. 2002. View Article : Google Scholar
5	Michalik L, Auwerx J, Berger JP, et al; International Union of Pharmacology. LXI Peroxisome proliferator-activated receptors. Pharmacol Rev. 58:726–741. 2006. View Article : Google Scholar : PubMed/NCBI
6	Kersten S, Desvergne B and Wahli W: Roles of PPARs in health and disease. Nature. 405:421–424. 2000. View Article : Google Scholar : PubMed/NCBI
7	Zhu YJ, Crawford SE, Stellmach V, et al: Coactivator PRIP, the peroxisome proliferator-activated receptor-interacting protein, is a modulator of placental, cardiac, hepatic, and embryonic development. J Biol Chem. 278:1986–1990. 2003. View Article : Google Scholar
8	Lemberger T, Desvergne B and Wahli W: Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol. 12:335–363. 1996. View Article : Google Scholar : PubMed/NCBI
9	Auboeuf D, Rieusset J, Fajas L, et al: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 46:1319–1327. 1997. View Article : Google Scholar
10	Kliewer SA, Forman BM, Blumberg B, et al: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA. 91:7355–7359. 1994. View Article : Google Scholar : PubMed/NCBI
11	Bishop-Bailey D and Hla T: Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem. 274:17042–17048. 1999. View Article : Google Scholar : PubMed/NCBI
12	Xin X, Yang S, Kowalski J and Gerritsen ME: Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem. 274:9116–9121. 1999. View Article : Google Scholar : PubMed/NCBI
13	Marcus SL, Miyata KS, Zhang B, Subramani S, Rachubinski RA and Capone JP: Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive elements of the rat hydratase/dehydrogenase and fatty acyl-CoA oxidase genes but differentially induce expression. Proc Natl Acad Sci USA. 90:5723–5727. 1993. View Article : Google Scholar
14	Kliewer SA, Umesono K, Mangelsdorf DJ and Evans RM: Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature. 355:446–449. 1992. View Article : Google Scholar : PubMed/NCBI
15	Ramachandran L, Manu KA, Shanmugam MK, et al: Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor gamma activation pathway in gastric cancer. J Biol Chem. 287:38028–38040. 2012. View Article : Google Scholar
16	Bishop-Bailey D: PPARs and angiogenesis. Biochem Soc Trans. 39:1601–1605. 2011. View Article : Google Scholar
17	Jung UJ, Torrejon C, Chang CL, Hamai H, Worgall TS and Deckelbaum RJ: Fatty acids regulate endothelial lipase and inflammatory markers in macrophages and in mouse aorta: a role for PPARgamma. Arterioscler Thromb Vasc Biol. 32:2929–2937. 2012. View Article : Google Scholar : PubMed/NCBI
18	Tontonoz P, Hu E and Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 79:1147–1156. 1994. View Article : Google Scholar : PubMed/NCBI
19	Gelman L, Fruchart JC and Auwerx J: An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci. 55:932–943. 1999. View Article : Google Scholar : PubMed/NCBI
20	Fajas L, Debril MB and Auwerx J: Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis. J Mol Endocrinol. 27:1–9. 2001. View Article : Google Scholar : PubMed/NCBI
21	Wang T, Xu J, Yu X, Yang R and Han ZC: Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit Rev Oncol Hematol. 58:1–14. 2006. View Article : Google Scholar : PubMed/NCBI
22	Kristiansen G, Jacob J, Buckendahl AC, et al: Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer Res. 12:6444–6451. 2006. View Article : Google Scholar
23	Watkins G, Douglas-Jones A, Mansel RE and Jiang WG: The localisation and reduction of nuclear staining of PPARgamma and PGC-1 in human breast cancer. Oncol Rep. 12:483–488. 2004.PubMed/NCBI
24	Segawa Y, Yoshimura R, Hase T, et al: Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate. 51:108–116. 2002. View Article : Google Scholar : PubMed/NCBI
25	Theocharis S, Kanelli H, Politi E, et al: Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer. 36:249–255. 2002. View Article : Google Scholar : PubMed/NCBI
26	Zhang GY, Ahmed N, Riley C, et al: Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer. 92:113–119. 2005. View Article : Google Scholar : PubMed/NCBI
27	Sasaki T, Fujimoto Y, Tsuchida A, Kawasaki Y, Kuwada Y and Chayama K: Activation of peroxisome proliferator-activated receptor gamma inhibits the growth of human pancreatic cancer. Pathobiology. 69:258–265. 2001. View Article : Google Scholar : PubMed/NCBI
28	Hahn WC, Dessain SK, Brooks MW, et al: Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol. 22:2111–2123. 2002. View Article : Google Scholar : PubMed/NCBI
29	Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M and Sugihara K: Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 10:8465–8471. 2004. View Article : Google Scholar : PubMed/NCBI
30	Asou H, Verbeek W, Williamson E, et al: Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. Int J Oncol. 15:1027–1031. 1999.PubMed/NCBI
31	Zang C, Liu H, Posch MG, et al: Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia. Leuk Res. 28:387–397. 2004. View Article : Google Scholar : PubMed/NCBI
32	Sato H, Ishihara S, Kawashima K, et al: Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer. 83:1394–1400. 2000. View Article : Google Scholar : PubMed/NCBI
33	Sarraf P, Mueller E, Smith WM, et al: Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell. 3:799–804. 1999. View Article : Google Scholar : PubMed/NCBI
34	Mueller E, Sarraf P, Tontonoz P, et al: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell. 1:465–470. 1998. View Article : Google Scholar : PubMed/NCBI
35	Ogino S, Shima K, Baba Y, et al: Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology. 136:1242–1250. 2009. View Article : Google Scholar
36	Inoue K, Kawahito Y, Tsubouchi Y, et al: Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun. 287:727–732. 2001. View Article : Google Scholar : PubMed/NCBI
37	Eibl G, Wente MN, Reber HA and Hines OJ: Peroxisome proliferator-activated receptor gamma induces pancreatic cancer cell apoptosis. Biochem Biophys Res Commun. 287:522–529. 2001. View Article : Google Scholar : PubMed/NCBI
38	Farrow B and Evers BM: Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun. 301:50–53. 2003. View Article : Google Scholar : PubMed/NCBI
39	Itami A, Watanabe G, Shimada Y, et al: Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Int J Cancer. 94:370–376. 2001. View Article : Google Scholar : PubMed/NCBI
40	Katz MH, Fleming JB, Lee JE and Pisters PW: Current status of adjuvant therapy for pancreatic cancer. Oncologist. 15:1205–1213. 2010. View Article : Google Scholar : PubMed/NCBI
41	Squadroni M and Fazio N: Chemotherapy in pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci. 14:386–394. 2010.PubMed/NCBI
42	Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 10:2307–2318. 2004. View Article : Google Scholar : PubMed/NCBI
43	Leung L, Radulovich N, Zhu CQ, et al: Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma. PLoS One. 7:e466772012. View Article : Google Scholar : PubMed/NCBI
44	Awasthi N, Zhang C, Ruan W, Schwarz MA and Schwarz RE: BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther. 11:2644–2653. 2012. View Article : Google Scholar : PubMed/NCBI
45	Wang H, Pei W, Luan Q, et al: A feasibility study on gene therapy of pancreatic carcinoma with Ad-PUMA. Cancer Biol Ther. 13:712–719. 2012. View Article : Google Scholar : PubMed/NCBI